SRR1330699
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.437
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.426
- COAGULATION+0.407
- INTERFERON_ALPHA_RESPONSE+0.383
- INFLAMMATORY_RESPONSE+0.336
- MYOGENESIS+0.335
- INTERFERON_GAMMA_RESPONSE+0.311
- PANCREAS_BETA_CELLS+0.308
- ESTROGEN_RESPONSE_LATE+0.304
- BILE_ACID_METABOLISM+0.276
Top 10 suppressed
- MYC_TARGETS_V1-0.601
- DNA_REPAIR-0.544
- MYC_TARGETS_V2-0.542
- UNFOLDED_PROTEIN_RESPONSE-0.520
- OXIDATIVE_PHOSPHORYLATION-0.503
- PROTEIN_SECRETION-0.463
- MTORC1_SIGNALING-0.462
- CHOLESTEROL_HOMEOSTASIS-0.442
- PI3K_AKT_MTOR_SIGNALING-0.392
- E2F_TARGETS-0.371
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1455698 | GTEX | — | 0.974 |
| 2 | SRR1374115 | GTEX | — | 0.973 |
| 3 | SRR817775 | GTEX | — | 0.972 |
| 4 | SRR1444559 | GTEX | — | 0.965 |
| 5 | SRR820292 | GTEX | — | 0.965 |
| 6 | SRR1389036 | GTEX | — | 0.964 |
| 7 | SRR819793 | GTEX | — | 0.963 |
| 8 | SRR1332856 | GTEX | — | 0.962 |
| 9 | SRR1467011 | GTEX | — | 0.961 |
| 10 | SRR1331289 | GTEX | — | 0.961 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.437 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.426 | Inavolisib | — uncovered |
| COAGULATION | 0.407 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.383 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.336 | Idelalisib | — uncovered |
| MYOGENESIS | 0.335 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.311 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.308 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.304 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.276 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.267 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.215 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.206 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.204 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.202 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.188 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.117 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.115 | Inavolisib | — uncovered |